Crossmark

CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases

Crossref DOI link: https://doi.org/10.1038/s41408-023-00800-2

Published Online: 2023-02-17

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ilyas, Rimal

McCullough, Kristen https://orcid.org/0000-0003-4252-2619
Badar, Talha https://orcid.org/0000-0003-1548-918X
Patnaik, Mrinal M. https://orcid.org/0000-0001-6998-662X
Alkhateeb, Hassan https://orcid.org/0000-0002-3609-8404
Mangaonkar, Abhishek https://orcid.org/0000-0003-2458-9887
Pardanani, Animesh

Tefferi, Ayalew https://orcid.org/0000-0003-4605-3821
Gangat, Naseema https://orcid.org/0000-0002-9104-6172
License Information

Text and Data Mining valid from 2023-02-17

Version of Record valid from 2023-02-17
More Information

Article History

Received: 2 January 2023

Revised: 7 February 2023

Accepted: 9 February 2023

First Online: 17 February 2023

Competing interests

: The authors declare no competing interests.